Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
44,878,307
-
Share change
-
+2,712,740
-
Total reported value
-
$265,481,374
-
Price per share
-
$5.93
-
Number of holders
-
63
-
Value change
-
+$15,180,997
-
Number of buys
-
32
-
Number of sells
-
39
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q1 2020
As of 31 Mar 2020,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,878,307 shares.
The largest 10 holders included
FMR LLC, ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., ARCH VENTURE CORP, Flagship Pioneering Inc., BlackRock Inc., Point72 Asset Management, L.P., VANGUARD GROUP INC, and Samsara BioCapital, LLC.
This page lists
63
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.